Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?
사설/논평
0/5 보강
APA
Lee PC, Huang YH (2025). Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?. Hepatology (Baltimore, Md.). https://doi.org/10.1097/HEP.0000000000001482
MLA
Lee PC, et al.. "Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?." Hepatology (Baltimore, Md.), 2025.
PMID
40729119 ↗
같은 제1저자의 인용 많은 논문 (5)
- Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
- Integration of local and systemic immunotherapy: setting new standards in liver-confined hepatocellular carcinoma.
- Serum fibrosis marker M2BPGi-based novel score predicts survival of unresectable HCC undergoing immunotherapy.
- Characterizing immune profiles in hepatocellular carcinoma patients benefiting from pembrolizumab and lenvatinib using machine learning.
- Treatment of Nasal Deviation With Underlying Bony Asymmetry Secondary to Augmentation Rhinoplasty in Asian Patients.